In an increasingly uncertain market, where concentration risk looms large, savvy investors are seeking refuge in quality blue-chip stocks. With about 50% of the market's earnings stemming from the top ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded ...

The global bioconjugation market is projected to grow at an estimated CAGR of close to 13% over the next five years. This growth is fueled by the rising need for targeted therapies, continuous ...

Learn more about whether Halozyme Therapeutics, Inc. or Nurix Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

Finding the best blue-chip stocks to buy is never a simple task, especially when markets are shifting. Economic uncertainty, changing interest-rate expectations and the rapid evolution of ...

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

Don Nesbitt, senior portfolio manager at F/m Investments, joins BNN Bloomberg to share his Hot Picks in healthcare.

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...